Have Questions?
Get Answers.


Contact Customer Service

Call: 1-800-543-1980

Email Us

-or-

Contact Technical Support

Call: 1-800-343-3858

Email Us

Sign Up for
Email Updates

Stay connected with the latest product information & company news
Register Now View Privacy Policy
Overview

Overview of Group B Streptococcus

Invasive Group B Streptococcal disease emerged in the 1970's as the leading cause of infectious disease in infants. Infants with early onset infection (<7 days of age) may show symptoms of respiratory distress, apnea or sepsis. Early-onset GBS disease is most commonly associated with sepsis and pneumonia, however it may lead to meningitis.

The fatality rate for infants with early-onset GBS disease is currently estimated at 4%-6%. Surviving infants may experience long-term disabilities including hearing loss, vision loss, or mental retardation. The primary risk factor for early-onset GBS disease is maternal colonization.

If detected, intrapartum transmission of Group B Streptococcus or early-onset GBS disease can be prevented by administration of antibiotic prophylaxis prior to delivery. Traditional culture has been the standard of care for most laboratories in North America for many years, but the significant potential for false negatives is creating a shift in testing.

Molecular Testing for Group B Streptococcus

Molecular testing is growing due to its ability to provide more accurate results than traditional culture methods. illumigene® Group B Streptococcus (GBS) exceeds the performance of current Group B Streptococcus test methods. illumigene® GBS fully complies with the CDC guidelines for antepartum testing at 35 - 37 weeks gestation while allowing the flexibility of testing with multiple broth-enriched specimen types (Lim, TransVag, Carrot).

illumigene® GBS provides definitive answers and confident results, putting the right information at the right time in the hands of physicians. Reliable results make it possible for mothers to be treated at the time of delivery, ensuring the best outcome for baby.

Featured Products
Illumigene Molecular Diagnostic System NEW molecular assay for the detection of C. difficile in stool
View Product
ELISA for the detection of C. difficile toxins A & B in stool specimens ELISA for the detection of C. difficile toxins A&B in stool specimens.
View Product
Rapid EIA for the detection of C. difficile toxins A & B in stool specimens Rapid EIA for the detection of C. difficile toxins A&B in stool specimens.
View Product
Rapid EIA for the detection of C. difficile common antigen in stool specimens Rapid EIA for the detection of C. difficile common antigen in stool specimens.
View Product
  pixel